ORGANOGENESIS HOLDINGS INC. Finance Lease, Right-of-Use Asset, Amortization
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Finance Lease, Right-of-Use Asset, Amortization of $1.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. finance lease, right-of-use asset, amortization for the quarter ending 2024-06-30 was $288.00K, a 396.55% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. finance lease, right-of-use asset, amortization for the quarter ending 2024-03-31 was $288.00K.
- ORGANOGENESIS HOLDINGS INC. finance lease, right-of-use asset, amortization for the quarter ending 2023-12-31 was $287.00K.
- ORGANOGENESIS HOLDINGS INC. finance lease, right-of-use asset, amortization for the quarter ending 2023-09-30 was $134.00K.
- ORGANOGENESIS HOLDINGS INC. finance lease, right-of-use asset, amortization for fiscal 2025 was $1.20M, a 3.91% increase from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. finance lease, right-of-use asset, amortization for fiscal 2024 was $1.15M, a 140.29% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. finance lease, right-of-use asset, amortization for fiscal 2023 was $479.00K, a 124.88% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. finance lease, right-of-use asset, amortization for fiscal 2022 was $213.00K, a 87.52% decline from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.20M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $1.15M 10-K · filed 2026-02-26 | |||
| 2024-06-30 | $288.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $576.00K 10-Q · filed 2024-08-08 | $863.00K derived: sum of 3 quarters · filed 2026-02-26 | $997.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $288.00K 10-Q · filed 2024-05-09 | $575.00K derived: sum of 2 quarters · filed 2026-02-26 | $709.00K derived: sum of 3 quarters · filed 2026-02-26 | $767.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $287.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $421.00K derived: sum of 2 quarters · filed 2026-02-26 | $479.00K derived: sum of 3 quarters · filed 2026-02-26 | $479.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $134.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $192.00K derived: sum of 2 quarters · filed 2024-08-08 | $192.00K 10-Q · filed 2023-11-09 | $192.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-06-30 | $58.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $58.00K 10-Q · filed 2024-08-08 | $58.00K derived: sum of 3 quarters · filed 2024-08-08 | $58.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-05-09 | $0.00 derived: sum of 3 quarters · filed 2024-05-09 | $106.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $106.00K derived: sum of 3 quarters · filed 2024-02-29 | $213.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $106.00K derived: sum of 2 quarters · filed 2023-11-09 | $213.00K 10-Q · filed 2023-11-09 | $524.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $213.00K 10-Q · filed 2023-08-09 | $524.00K derived: sum of 3 quarters · filed 2023-08-09 | $1.32M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $107.00K 10-Q · filed 2023-05-10 | $418.00K derived: sum of 2 quarters · filed 2023-05-10 | $1.21M derived: sum of 3 quarters · filed 2023-05-10 | $1.51M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $311.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.10M derived: sum of 2 quarters · filed 2023-03-01 | $1.41M derived: sum of 3 quarters · filed 2023-03-01 | $1.71M 10-K · filed 2023-03-01 |
| 2021-09-30 | $793.00K 10-Q · filed 2021-11-09 | $1.10M derived: sum of 2 quarters · filed 2021-11-09 | $1.40M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $304.00K 10-Q · filed 2021-08-09 | $603.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $299.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |